MacroGenics, Inc.
HealthcareNASDAQ:MGNX · NASDAQ Global Select
-$0.05 today
Vol 0.51M · Avg 0.99M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-134.2%
avg -52.9%
ROIC
-33.0%
avg -43.6%
ROA
-29.1%
avg -29.4%
Analysis
ROA is currently the strongest return metric at -29.1% versus its period average of -29.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Eric Blasius Risser | Chief Executive Officer, President & Director | $977,468.00 | — | 53 | $83,602.00 | 0.13% |
Ezio Bonvini | Senior Vice President of Research & Chief Scientific Officer | $881,400.00 | — | 72 | $152,232.00 | 0.24% |
James Karrels | Senior VP & CFO | $845,548.00 | — | 59 | $206,037.00 | 0.32% |
Thomas Spitznagel | Senior Vice President of Technical Operations | $550,974.00 | — | 59 | $3,750.00 | <0.01% |
Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning | — | — | — | — | — |
Jeffrey Stuart Peters | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer | — | — | 55 | $36,252.00 | 0.06% |
Beth Smith | Vice President, Controller & Treasurer | — | — | 58 | $13,204.00 | 0.02% |
Frank George Perabo FEBU | Vice President & Interim Head of Clinical Development | — | — | 62 | — | — |
Steve Harig | Senior Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$150,515.00
Sells
0
$0.00
Net Sentiment
+$150,515.00
Net buying
Most Active
HEIDEN WILLIAM K
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Aug 20, 2025 | HEIDEN WILLIAM K Direct | Buy | 49.5K | $1.49 | $73,755.00 | |
| Aug 19, 2025 | HEIDEN WILLIAM K Direct | Buy | 50.5K | $1.52 | $76,760.00 |
Analysis
Insiders reported 2 buys worth $150,515.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $150,515.00. HEIDEN WILLIAM K was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +19.1% | +6.2% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +19.1% over three years. Forward estimates point to Revenue at +6.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Clene Inc.
NASDAQ:CLNN
$60.20M
Who manages MGNX?
MacroGenics, Inc. (MGNX) lists 9 active executives. The top listed executive is Ezio Bonvini, Senior Vice President of Research & Chief Scientific Officer.
Are MGNX insiders buying or selling?
Recent insider activity shows net buying of $4.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.